Beijing, China

Chengyuan Lu

USPTO Granted Patents = 10 

Average Co-Inventor Count = 9.5

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2021-2024

Loading Chart...
10 patents (USPTO):

Title: Innovations by Chengyuan Lu in Cancer Treatment

Introduction

Chengyuan Lu is a prominent inventor based in Beijing, China, known for his significant contributions to the field of biopharmaceuticals. He holds a total of 10 patents, focusing primarily on innovative treatments for cancer. His work has the potential to impact the lives of many patients suffering from various forms of cancer.

Latest Patents

Among his latest patents are groundbreaking developments in anti-PD-1 antibodies and anti-CD40 antibodies. The anti-PD-1 antibodies are designed to target the Programmed Cell Death Protein 1, offering new methods for treating cancer. Additionally, his anti-CD40 antibodies focus on the TNF Receptor Superfamily Member 5, providing further avenues for therapeutic applications in oncology.

Career Highlights

Chengyuan Lu has worked with notable companies in the biopharmaceutical sector, including Eucure Biopharma Co., Ltd. and Biocytogen Pharmaceuticals Co., Ltd. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to cutting-edge research.

Collaborations

Chengyuan has collaborated with several professionals, including Chen Wang and Chunyan Dong, enhancing the scope and impact of his research. These collaborations have fostered a dynamic environment for innovation and development in cancer therapies.

Conclusion

Chengyuan Lu's work exemplifies the intersection of innovation and healthcare, particularly in the realm of cancer treatment. His patents and collaborations highlight his commitment to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…